Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mi Bone Capsule (Migu Capsule) is a Traditional Chinese Medicine (TCM) hospital preparation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is formulated to treat musculoskeletal conditions characterized by the "Liver-Kidney Deficiency" pattern in TCM theory, most notably knee osteoarthritis and osteoporosis. The capsule is composed of a specific blend of herbal extracts, typically including ingredients such as *Epimedium*, *Psoralea corylifolia*, and *Drynaria fortunei*, which are traditionally used to strengthen bone and tendon health. In clinical research, the drug is evaluated for its efficacy in reducing joint pain and improving physical function in postmenopausal women, often measured by WOMAC scores and Visual Analogue Scale (VAS) pain assessments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mi Bone Capsule.